Skip to main content

Advertisement

SpringerLink
Log in

A Review of Safety and Effectiveness of Intravenous and Intraventricular Tigecycline in Healthcare-Associated Acinetobacter baumannii Meningitis and Ventriculitis

  • Bacterial Infections (H Bach, Section Editor)
  • Published:
Current Treatment Options in Infectious Diseases Aims and scope Submit manuscript

Abstract

Objective

To review the clinical data on the safety and effectiveness of intravenous (IV) and intraventricular (IVT) tigecycline in healthcare-associated Acinetobacter baumannii meningitis and ventriculitis.

Methods

A literature search was performed in PubMed (from 2005 to December 2018). The bibliographies of the retrieved articles were searched for additional relevant studies. Articles were included if they described the use of tigecycline (IV and/or IVT) in patients with healthcare-associated A. baumannii meningitis or ventriculitis. Clinical studies as well as case series and case reports were included, while animal and in vitro studies were excluded.

Results

The use of IV and/or IVT tigecycline was described in 39 patients infected with healthcare-associated A. baumannii meningitis or ventriculitis in 14 reports; 12 were case reports, one was case series, and one was retrospective multicenter study evaluating 23 carbapenem-resistant A. baumannii healthcare-associated meningitis cases treated with IV tigecycline including regimens. Using tigecycline was successful in most cases. Treatment failed in two patients and two patients died.

Conclusion

Despite the limited studies, IV and IVT tigecycline has been used successfully and safely for the treatment of healthcare-associated A. baumannii meningitis and ventriculitis. However, large randomized controlled trials are necessary to clearly evaluate the safety and effectiveness of IV and IVT tigecycline in healthcare-associated A. baumannii meningitis and ventriculitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med. 2010;362:146–54. https://doi.org/10.1056/NEJMra0804573.

    Article  PubMed  Google Scholar 

  2. Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, et al. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9:245–55. https://doi.org/10.1016/S1473-3099(09)70055-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Michael Scheld W, et al. Infectious Diseases Society of America’s clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis. 2017 Feb 14 [Epub ahead of print];64:e34–65. https://doi.org/10.1093/cid/ciw861.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. De Bonis P, Lofrese G, Scoppettuolo G, Spanu T, Cultrera R, Labonia M, et al. Intraventricular versus intravenous colistin for the treatment of extensively drug resistant Acinetobacter baumannii meningitis. Eur J Neurol. 2016;23:68–75. https://doi.org/10.1111/ene.12789.

    Article  PubMed  Google Scholar 

  5. Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013;4:499–508. https://doi.org/10.1016/j.ijantimicag.2013.02.006.

    Article  CAS  Google Scholar 

  6. Lauretti L, D'Alessandris QG, Fantoni M, D'Inzeo T, Fernandez E, Pallini R, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg. 2017;127:370–3. https://doi.org/10.3171/2016.6.JNS16352.

    Article  PubMed  Google Scholar 

  7. Polat M, Ozkaya-Parlakay A. Tigecycline salvage therapy for ventriculoperitoneal shunt meningitis due to extensively drug-resistant Acinetobacter baumannii. Eur J Pediatr. 2019;178:117–8. https://doi.org/10.1007/s00431-018-3271-2.

    Article  PubMed  Google Scholar 

  8. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221–9. https://doi.org/10.1093/jac/dkl403.

    Article  CAS  PubMed  Google Scholar 

  9. Ray L, Levasseur K, Nicolau DP, Scheetz MH. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother. 2010;44:582–6. https://doi.org/10.1345/aph.1M480.

    Article  PubMed  Google Scholar 

  10. Kooli I, Brahim HB, Kilani M, Gannouni C, Aouam A, Toumi A, et al. Successful treatment of postoperative multidrug-resistant Acinetobacter baumannii meningitis by tigecycline. J Glob Antimicrob Resist. 2016;5:62–3. https://doi.org/10.1016/j.jgar.2015.12.003.

    Article  PubMed  Google Scholar 

  11. Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med. 2007;27:456–8.

    Article  Google Scholar 

  12. Tsolaki V, Karvouniaris M, Manoulakas E, Kotlia P, Karadontas V, Fotakopoulos G, et al. Intraventricular CNS treatment with colistin-tigecycline combination: a case series. J Crit Care. 2018;47:338–41. https://doi.org/10.1016/j.jcrc.2018.07.025.

    Article  CAS  PubMed  Google Scholar 

  13. Perier F, Couffin S, Martin M, Bardon J, Cook F, Mounier R. Multidrug-resistant Acinetobacter baumannii ventriculostomy-related infection, treated by a colistin, tigecycline, and intraventricular fibrinolysis. World Neurosurg. 2019;121:111–6. https://doi.org/10.1016/j.wneu.2018.09.218.

    Article  PubMed  Google Scholar 

  14. •• Sipahi OR, Mermer S, Demirdal T, Ulu AC, Fillatre P, Ozcem SB, et al. Tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis: results of the Ege study. Clin Neurol Neurosurg. 2018;172:31–8. https://doi.org/10.1016/j.clineuro.2018.06.008 This is the only cohort study evaluating the use of intravenous tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii meningitis.

    Article  Google Scholar 

  15. • Long W, Yuan J, Liu J, Liu J, Wu M, Chen X, et al. Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: a case report and review of literature. Front Neurol. 2018;9:518. https://doi.org/10.3389/fneur.2018.00518 This case report introduced the continuous ventricular irrigation as a novel method for the treatment of ventriculitis caused by MDR A. baumannii.

  16. Guo W, Guo SC, Li M, Li LH, Qu Y. Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with polymyxin B and tigecycline- a case report. Antimicrob Resist Infect Control. 2018;7(22):22. https://doi.org/10.1186/s13756-018-0313-5.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Tutuncu EE, Kuscu F, Gurbuz Y, Ozturk B, Haykir A, Sencan I. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis. 2010;14(Suppl 3):e224–6. https://doi.org/10.1016/j.ijid.2009.07.022.

    Article  PubMed  Google Scholar 

  18. Liu Y, Pu Z, Zhao M. Case report of successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with intravenous plus intraventricular tigecycline. Antimicrob Agents Chemother. 2018;62:e01625–18. https://doi.org/10.1128/AAC.01625-18.

    Article  PubMed  PubMed Central  Google Scholar 

  19. De Pascale G, Pompucci A, Maviglia R, Spanu T, Bello G, Mangiola A, et al. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intrathecal and intravenous colistin. Minerva Anestesiol. 2010;76:957–60.

    PubMed  Google Scholar 

  20. Shrestha GS, Tamang S, Paneru HR, Shrestha PS, Keyal N, Acharya SP, et al. Colistin and tigecycline for management of external ventricular device-related ventriculitis due to multidrug-resistant Acinetobacter baumannii. J Neurosci Rural Pract. 2016;7:450–2. https://doi.org/10.4103/0976-3147.176194.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Fang YQ, Zhan RC, Jia W, Zhang BQ, Wang JJ. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore). 2017;96:e7703. https://doi.org/10.1097/MD.0000000000007703.

    Article  Google Scholar 

  22. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71:292–301. https://doi.org/10.1111/2049-632X.12125.

    Article  CAS  PubMed  Google Scholar 

  23. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents. 2011;37:102–9. https://doi.org/10.1016/j.ijantimicag.2010.10.014.

    Article  CAS  PubMed  Google Scholar 

  24. Cascio A, Conti A, Sinardi L, Iaria C, Angileri FF, Stassi G, et al. Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. Int J Infect Dis. 2010;14:e572–9. https://doi.org/10.1016/j.ijid.2009.06.032.

    Article  PubMed  Google Scholar 

  25. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56:470–80.

    Article  CAS  Google Scholar 

  26. De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90. https://doi.org/10.1186/cc13858.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wu Y, Chen K, Zhao J, Wang Q, Zhou J. Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy: a case report. J Chemother. 2018;30:49–52. https://doi.org/10.1080/1120009X.2017.1338846.

    Article  PubMed  Google Scholar 

  28. Tak V, Mathur P, Varghese P, Misra MC. Elizabethkingia meningoseptica: an emerging pathogen causing meningitis in a hospitalized adult trauma patient. Indian J Med Microbiol. 2013;31:293–5. https://doi.org/10.4103/0255-0857.115653.

    Article  CAS  PubMed  Google Scholar 

  29. Jaspan HB, Brothers AW, Campbell AJ, McGuire JK, Browd SR, Manley TJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J. 2010;29:379–81. https://doi.org/10.1097/INF.0b013e3181c806d8.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Emiroglu M, Alkan G, Turk Dagi H. Tigecycline therapy in an infant for ventriculoperitoneal shunt meningitis. Pediatrics. 2017;139:e20160963. https://doi.org/10.1542/peds.2016-0963.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Care Services, King Saud Medical City, Riyadh, 12746, Saudi Arabia

    Mohammad Abdallah PharmD, BCCCP & Hamzeh Alsaleh PharmD, BCCCP

Authors
  1. Mohammad Abdallah PharmD, BCCCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamzeh Alsaleh PharmD, BCCCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Abdallah PharmD, BCCCP.

Ethics declarations

Conflict of interest

Mohammad Abdallah declares that he has no conflict of interest. Hamzeh Alsaleh declares that he has no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Bacterial Infections

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdallah, M., Alsaleh, H. A Review of Safety and Effectiveness of Intravenous and Intraventricular Tigecycline in Healthcare-Associated Acinetobacter baumannii Meningitis and Ventriculitis. Curr Treat Options Infect Dis 11, 331–343 (2019). https://doi.org/10.1007/s40506-019-00192-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40506-019-00192-7

Keywords

Search

Navigation